Physician profile
Michael C Scheve
NPI 1538454905
$3,475.02
in general payments reported to CMS, 2019-2025
30 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.13 · 2020: $201 · 2021: $732 · 2022: $805 · 2023: $637 · 2024: $661 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $634.68 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $495.87 | 2020-2024 | Mounjaro, Emgality, Jardiance |
| Novo Nordisk INC | $269.10 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.70 | 2020-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $220.07 | 2019-2025 | Belsomra, Gardasil 9, M-M-R II |
| Pfizer INC. | $145.45 | 2020-2025 | |
| Glaxosmithkline, LLC. | $141.37 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $138.68 | 2021-2023 | Xarelto |
| Abbott Laboratories | $124.48 | 2021-2023 | Freestyle Libre 2 |
| Pulmonx Corporation | $121.87 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $117.39 | 2021-2025 | |
| Amgen INC. | $101.83 | 2019-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $87.57 | 2023-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $76.64 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Sumitomo Pharma America, INC. | $60.16 | 2023-2025 | Gemtesa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.00 | 2021-2025 | |
| Eisai INC. | $51.88 | 2020-2021 | |
| Kvk-Tech, INC. | $51.23 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.88 | 2021 | |
| Currax Pharmaceuticals LLC | $45.04 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $38.31 | 2025 | Fanapt |
| Sanofi-Aventis U.S. LLC | $33.12 | 2021 | |
| Exact Sciences Corporation | $32.09 | 2023-2024 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $30.42 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $29.69 | 2024 | Quviviq |
| Ge Healthcare | $28.78 | 2021 | |
| Shield Therapeutics INC | $22.93 | 2024 | |
| Medtronic, INC. | $21.22 | 2024 | Minimed 780g |
| Phathom Pharmaceuticals, INC. | $13.68 | 2024 | Voquezna |
| Amarin Pharma, INC. | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Scheve listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.